Iron-mediated ROS generation in photodynamic therapy
At the 16th International Symposium on Applied Bioinorganic Chemistry (ISABC), held in Ioannina, Greece, in June 2023 and organised by the University of Ioannina, applied coordination science was placed in a practical medical context. Iron-mediated reactive oxygen species (ROS) generation in photodynamic therapy illustrates how metal ions, molecular photosensitisers and light can combine to create a local oxidative treatment. The meeting’s focus on applied bioinorganic chemistry made this area relevant to researchers working between molecular design, photophysics and translational medicine. Learn more about Scholarship Opportunities For Early Career Researchers From Developing Countries.
For Australian laboratories, the topic connects established strengths in chemistry, cancer biology and biomedical engineering with the work needed to move an idea towards clinical use. Teams in Sydney, Melbourne, Brisbane and Adelaide can contribute to photosensitiser performance, oxygen delivery, light dosimetry and safety studies. The aim is not simply to maximise oxidative damage, but to control where radicals form, which cells they affect and how the treatment behaves in a complex tumour microenvironment. Learn more about Aic2017.org.
From conference themes to iron photochemistry
Photochemistry starts when a photosensitiser absorbs light and transfers energy or electrons to nearby molecules. Type I routes form radical species, while Type II routes can generate singlet oxygen. Iron adds an amplification step when ferrous and ferric ions cycle between oxidation states.
| Pathway | Main reactive species | Role of iron | Design focus |
|---|---|---|---|
| Type I | Superoxide, hydrogen peroxide and hydroxyl radicals | Fe²⁺/Fe³⁺ cycling drives Fenton chemistry | Confine radical production |
| Type II | Singlet oxygen | Iron is not required for energy transfer, but local iron can influence oxidative conditions | Maintain oxygen delivery and selectivity |
| Combined photochemistry | Singlet oxygen and radical species | Coupled pathways may assist in oxygen-poor sites | Balance efficacy with dark toxicity |
The key distinction is that Type II photochemistry does not require iron, whereas iron can magnify Type I chemistry. Fe²⁺ reacts with hydrogen peroxide through the Fenton reaction to produce hydroxyl radicals, and photosensitiser-generated superoxide can feed that network. Researchers must therefore measure dark reactivity, intracellular metal distribution and light dose.
For applied bioinorganic chemistry, mechanistic clarity must connect coordination behaviour to a measurable outcome. A compound may bind indiscriminately, precipitate in physiological media or reach the target cell poorly. Chelators, carriers and redox-responsive structures are therefore part of the treatment design, rather than peripheral formulation choices.
Mechanistic choices for photosensitiser design
Design should begin with the intended biological compartment. Mitochondria, lysosomes, membranes and tumours differ in redox potential, oxygen tension and iron availability. The absorption spectrum must fit the tissue’s optical window; Australia’s strong UV does not replace calibrated red or near-infrared light for deeper targets.
Ligand choice determines redox cycling, solubility and trafficking, so iron complexes may shield metal centres or release Fe²⁺ after cellular reduction. Spectroscopic probes, spin trapping, imaging and calibrated dosimetry should be combined with light-only, dark, iron-only and sensitiser-only controls. Common protocols and reference materials would help teams in Melbourne and Sydney produce comparable datasets in oxygenated and oxygen-limited cultures.
How the tumour microenvironment changes the target
Solid tumours are not uniform. Stroma, blood flow, oxygen gradients and variable iron content can leave some cells beyond effective light penetration while others receive a damaging dose. Hypoxia may favour radical pathways over singlet oxygen, making iron-mediated ROS useful in oxygen-poor regions, but it can also weaken spatial selectivity.
Opportunity must be weighed against collateral injury. Healthy tissue in Australian hospitals also experiences oxidative stress, and patients may bring inflammation, metal imbalance or medication that alters ROS handling. Studies should combine chemical fate with the location and persistence of radicals, using co-cultures, immune cells and organoids. NHMRC-supported teams can add imaging expertise, but ethics approval and governance for patient-derived material must precede clinical work.
From oncology to antimicrobial applications
The same chemistry can be evaluated against resistant microbial infections, an urgent issue across Australian hospitals and aged-care facilities. Iron-dependent photodynamic antimicrobial approaches can damage membranes, enzymes and nucleic acids, and may reduce conventional antibiotic resistance when paired with existing agents. Species identification, biofilm penetration and light availability at an infection site remain decisive constraints.
Environmental applications add another market-facing dimension, including wastewater treatment, where photosensitiser recovery, regulatory acceptance and cost influence feasibility. A treatment requiring expensive illumination may suit a hospital application better than outdoor deployment, so local validation should precede any commercial claim or market expansion.
Practical routes for Australian laboratories
An Australian programme should move from mechanism to reproducible biology before scale-up. A defensible chemical model, relevant cell states, realistic oxygen and iron conditions, and fixed irradiation parameters create a stronger basis for funding and regulatory engagement.
- Mechanistic validation: Quantify sensitiser photochemistry, iron redox cycling and ROS with complementary chemical and cellular assays.
- Biological modelling: Compare relevant cell states, oxygen levels, iron loading and light doses before using complex tissue models.
- Reproducibility: Report irradiation parameters, analysis choices and shared reference materials across collaborating sites.
Partnerships can connect synthesis with clinical questions. Australian medtech firms, hospital departments and contract laboratories may hold different parts of the evidence chain, while TGA classification and state ethics requirements determine the pathway for a drug-device claim. Before shipping clinical specimens, cultures or biological materials, check Australian Border Force biosecurity and customs requirements.
- Funding route: Check NHMRC grants, university schemes and targeted photonics or biomedical research programmes.
- Translation partner: Bring in a clinician-scientist or contract manufacturer with expertise in scale-up, packaging and dose delivery.
- Market pathway: Define whether the intended product is a medicine, medical device, combination product or antimicrobial service.
ISABC resources widen access to the scientific network. Eligible researchers from developing countries can review the symposium’s [early-career funding] page; Australian applicants should check the separate travel-award and poster criteria. Poster prizes can provide early-career scientists with feedback on both mechanism and translation.
Carry the symposium work forward
Historical perspective is useful when planning the next collaboration. The [earlier applied meeting] offers another reference point in the international exchange of applied bioinorganic research, while ISABC records the 2023 Ioannina meeting’s participation, awards and programme. The official symposium site remains a gateway to the event’s scientific and administrative information.
Researchers inspired by the meeting should review the available programme and abstract themes, identify a local collaborator and define the next experiment or partnership. For the 2023 symposium, Zita Congress & Event Management served as the official secretariat for registration, accommodation and abstract-related enquiries. Contact the secretariat about archived records and award documentation, then use the Ioannina exchange to build a reproducible research plan, a realistic budget and a responsible path towards clinical or antimicrobial application.